CD40 Agonism in Immuno-Oncology: Why Expectations Stay High
This article reviews CD40 agonism in immuno-oncology research: licensing dendritic cells, reversing the cold tumor phenotype, the safety trade-offs of systemic agonism and what standardized CD40 reagents contribute to preclinical workflows.
- Recent Advances
- Product Information
Keywords: CD40 agonist, immuno-oncology, dendritic cell licensing, cold tumor, combination therapy, UA010194
Note: The full article is published in Chinese. Please refer to the Chinese version for complete experimental details, figures and product references. For product inquiries, visit www.ua-bio.com.
This article is reviewed and published by the technical expert team of UA
Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.
Purchase recombinant protein, choose 
UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.
Business license (three certificates in one) 
